New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins

References

• Arnulf I, Bonnet AM, Damier P et al. Hallucinations, REM sleep, and Parkinson’s disease. Neurology55, 281–288 (2000).
   PubMed Web of Science ®Google Scholar
• Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry70, 734–738 (2001).
   PubMed Web of Science ®Google Scholar
• Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov. Disord.14(1), 117–121 (1999).
   PubMed Web of Science ®Google Scholar
• Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson’s disease: a populational study. Ann. Neurol.14, 136 (1983) (Abstract).
   Google Scholar
• Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson’s disease. Neurology57, 2078–2082 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson’s disease. Arch. Neurol.53, 1265–1268 (1996).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A, D’Andreamatteo G et al. Incidence of RBD and hallucination in patients affected by Parkinson’s disease: 8-year follow-up. Neurol. Sci.23(Suppl. 2), S91–S94 (2002).
   PubMed Web of Science ®Google Scholar
• Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry70, 734–738 (2001).
   PubMed Web of Science ®Google Scholar
• Doe de Maindreville A, Fenelon G, Mahieux F. Hallucinations in Parkinson’s disease: a follow-up study. Mov. Disord.20(2), 212–217 (2005).
   PubMedGoogle Scholar
• Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology43, 2227–2229 (1993).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology45(4), 669–671(1995).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: clues to separate origins. J. Neurol. Sci.25, 143–150 (2006).
   Google Scholar
• Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch. Neurol.23, 193–200 (1970).
   PubMed Web of Science ®Google Scholar
• Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J. Neural. Transm.43, 143–151 (1978).
   PubMed Web of Science ®Google Scholar
• Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry135(6), 669–675 (1978).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long term drug therapy. Am. J. Psychiatry139, 494–497 (1982).
   PubMed Web of Science ®Google Scholar
• Rondot P, De Recondo J, Coignet A, Zeigler M. Mental disorder in Parkinson’s disease after treatment with L-dopa. Adv. Neurol.40, 259–269 (1984).
   PubMedGoogle Scholar
• Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug induced hallucinations in parkinsonian patients. Neurology51(3), 811–814 (1998).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson’s disease. Drug-induced psychiatric states. Adv. Neurol.65, 115–138 (1995).
   PubMedGoogle Scholar
• Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S. Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J. Neurol.246, 365–368 (1999).
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. J. Neurol.252(10), 1223–1228 (2005).
   PubMed Web of Science ®Google Scholar
• Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in parkinsonism treated with L-dopa. J. Neurol. Neurosurg. Psychiatry34(5), 502–507 (1971).
   PubMed Web of Science ®Google Scholar
• Sacks OW, Kohl MS, Messeloff CR, Schwartz WF. Effects of levodopa in parkinsonian with dementia. Neurology22(5), 516–519 (1972).
   PubMed Web of Science ®Google Scholar
• Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol.28(5), 215–219 (2005).
   PubMed Web of Science ®Google Scholar
• Porteous HB, Ross DN. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. Br. Med. J.2, 138–140 (1956).
   PubMedGoogle Scholar
• Goetz CG, Pappert EJ, Blasucci LM et al. Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology50, 515–517 (1998).
   PubMed Web of Science ®Google Scholar
• Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J. Neural. Transm.111, 1447–1453 (2004).
   PubMed Web of Science ®Google Scholar
• Fénelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology66(1), 93–98 (2006).
   PubMed Web of Science ®Google Scholar
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis.9(3 Suppl), 417–423 (2006).
   PubMedGoogle Scholar
• Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J. Neural. Transm.111(10–11), 1219–1235 (2004)
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord.16(4), 622–630 (2001).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementia. Int. J. Geriat. Psychiatry16, 528–536 (2001).
   PubMed Web of Science ®Google Scholar
• Boeve BF, Silber MH, Parisi JE et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology61(1), 40–45 (2003).
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rüb U et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24, 197–211 (2003).
   PubMed Web of Science ®Google Scholar
• Onofrj M. Disturbi Mentali nelle Sindromi Parkinsoniane. Springer-Verlag, Milano, Italia (2003).
   Google Scholar
• Braak H, Rüb U, Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology64, 1404–1410 (2005).
   PubMed Web of Science ®Google Scholar
• Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in nondemented parkinsonian patients. Int. J. Geriatr. Psychiatry20, 668–673 (2005).
   PubMed Web of Science ®Google Scholar
• Williams D, Lees A. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol.4, 605–610 (2005)
   PubMed Web of Science ®Google Scholar
• Nomura T, Inoue Y, Mitani H, Kawahara Williams D, Lees A. Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol.4, 605–610 (2005).
   PubMedGoogle Scholar
• Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry55, 181–184 (1992).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Burke PF, Leurgans S et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case–control study. Arch. Neurol.58(2), 209–213 (2001)
   PubMed Web of Science ®Google Scholar
• Runge E. Psychosen bei Gehirnerkrankungen. In: Handbuch der Geisteskrankheiten. Bumke O (Ed.). Berlin Springer, Berlin, Germany 7, 526–680 (1928).
   Google Scholar
• Gamper E. Paralysis agitans. In: Handbuch der Neurologie. Bumke O, Foerster O (Eds). Berlin, Springer, Germany 16, 757–827 (1936).
   Google Scholar
• Ball B. De l ‘insanité dans la paralysie agitante. Encéphale2, 22–32 (1882).
   Google Scholar
• Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson’s disease: prevalence, phenomenology and risk factors. Brain123(Pt 4), 733–745 (2000).
   PubMed Web of Science ®Google Scholar
• Barnes J, David AS. Visual hallucinations in Parkinson’s disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry70, 727–733 (2001).
   PubMed Web of Science ®Google Scholar
• Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology67(9), 1605–1611 (2006).
   PubMed Web of Science ®Google Scholar
• Parant V. La paralysie agitante examinée comme cause de folie. Ann. Med. Psychol. (Paris)10, 45–63 (1883).
   Google Scholar
• Régis E. Précis de psychicatrie (4th Edition). Doin, Paris, France (1909).
   Google Scholar
• König H. Zur Psychopatologie der Paralysie Agitante. Arch. Psychiat. Nervenkr.50, 285–305 (1913).
   Google Scholar
• Lewy FH. Die Lehre vom Tonus und der Bewegung. Zugleich systematische Untersuchunges zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis agitans. Springer, Berlin, Germany (1923).
   Google Scholar
• Giladi N, Treves TA, Paleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson’s disease. J. Neural. Transm.107(1), 59–71(2000).
   PubMed Web of Science ®Google Scholar
• Melamed E. Neurobehavioral abnormalities in Parkinson’s disease. In: Movement Disorders. Watts RL, Koller C (Eds). McGraw Hill, NY, USA 257–262 (1996).
   Google Scholar
• Ozer F, Meral H, Hanoglu L et al. Cognitive impairment patterns in Parkinson’s disease with visual hallucinations. J. Clin. Neurosci.14(8), 742–746 (2007).
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Howard RJ. The perceptual consequences of visual loss: ‘positive’ pathologies of vision. Brain122(Pt 7), 1247–1260 (1999).
   PubMed Web of Science ®Google Scholar
• Schultz G, Melzack R. Visual hallucinations and mental state. A study of 14 Charles Bonnet syndrome hallucinators. J. Nerv. Ment. Dis.181(10), 639–643 (1993).
   PubMed Web of Science ®Google Scholar
• Teunisse RJ, Cruysberg JR, Verbeek A, Zitman FG. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br. J. Psychiatry166(2), 254–257 (1995).
   PubMedGoogle Scholar
• Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J. Neurol. Neurosurg. Psychiatry73, 535–541 (2002).
   PubMed Web of Science ®Google Scholar
• Schultz G, Needham W, Taylor R, Shindell S, Melzack R. Properties of complex hallucinations associated with deficits in vision. Perception25(6), 715–726 (1996).
   PubMed Web of Science ®Google Scholar
• White NJ. Complex visual hallucinations in partial blindness due to eye disorders. Br. J. Psychiatry36, 284–286 (1980).
   Google Scholar
• Teunisse RJ, Zitman FG, Raes DC. Clinical evaluation of 14 patients with the Charles Bonnet syndrome (isolated visual hallucinations). Compr. Psychiatry35, 70–75 (1994).
   PubMed Web of Science ®Google Scholar
• Cole M. When the left brain is not right the right brain may be left: report of personal experience of occipital hemianopia. J. Neurol. Neurosurg. Psychiatry67, 169–173 (1999).
   PubMed Web of Science ®Google Scholar
• Ffytche DH. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin. Neurosci.9, 173–189 (2007)
   PubMedGoogle Scholar
• McKee AC, Levine DN, Kowall NW, Richardson EP Jr. Peduncular hallucinosis associated with isolated infarction of the substantia nigra pars reticulata. Ann. Neurol.27, 500–504 (1990).
   PubMedGoogle Scholar
• Liedholm LJ, Anjegard IM, de Flon P, Smedby T. Two cases of peduncular hallucinosis. Vivid, colorful and dancing images and figures. Lakartidningen96(14), 1712–1715 (1999).
   PubMedGoogle Scholar
• Benke T. Peduncular hallucinosis: a syndrome of impaired reality monitoring. J. Neurol.253, 1561–1571 (2006).
   PubMed Web of Science ®Google Scholar
• Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain121(Pt 10), 1819–1840 (1998).
   PubMed Web of Science ®Google Scholar
• Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain123(Pt 10), 2055–2064 (2000).
   PubMed Web of Science ®Google Scholar
• Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: in fMRI study of visual hallucinations. Nat. Neurosci.1, 738–742 (1998).
   PubMed Web of Science ®Google Scholar
• Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of “benign hallucinations” in Parkinson disease. Arch. Neurol.63, 713–716 (2006).
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry64, 533–535 (1998).
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord.20, 130–140 (2005).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson’s disease recedes shortly after drug withdrawal (Review series). Psychiatry2, 22–24 (2002).
   Google Scholar
• Graham JM, Grűnewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry63, 434–440 (1997).
   PubMed Web of Science ®Google Scholar
• Poewe W. Psychosis in Parkinson’s disease. Mov. Disord.18(Suppl. 6), S80–S87 (2003).
   PubMedGoogle Scholar
• Nebe A, Ebersbach G. Selective diplopia in Parkinson’s disease: a special subtype of visual hallucination? Mov. Disord.8, 1175–1178 (2007).
   Google Scholar
• Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson’s disease. J. Pediatr. Ophthalmol. Strabismus33(3), 144–147 (1996).
   PubMed Web of Science ®Google Scholar
• Racette BA, Gokden MS, Tychsen LS, Perlmutter JS. Convergence insufficiency in idiopathic Parkinson’s disease responsive to levodopa. Strabismus7(3), 169–174 (1999).
   PubMedGoogle Scholar
• Goetz CG, Li JM, Wuu J, Leurgans S. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov. Disord.6, 863–865 (2006).
   Google Scholar
• Chan D, Rossor MN “-but who is that on the other side of you?” Extracampine hallucinations revisited. Lancet360, 2064–2066 (2002).
   PubMedGoogle Scholar
• Critchley EM, Rossall CJ. Hallucinations. Br. J. Hosp. Med.3, 264–270 (1978).
   Google Scholar
• Husain AM, Miller PP, Carwile ST. REM sleep behavior disorder: potential relationship to post-traumatic stress disorder. J. Clin. Neurophysiol.2, 148–157 (2001).
   Google Scholar
• Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson’s disease. Mov. Disord.7, 831–832 (2003).
   Google Scholar
• Kanazawa A, Hata T. Coexistence of the Ekbom syndrome and lilliputian hallucination. Psychopathology4, 209–211 (1992).
   Google Scholar
• Mosimann UP, Rowan EN, Partington CE et al. Characteristics of visual hallucinations in Parkinson’s disease dementia and dementia with Lewy bodies. Am. J. Geriat. Psychiatry2, 153–160 (2006).
   Google Scholar
• Mahowald MW, Schenk CH. Status dissociatus – a perspective on state of being. Sleep14, 69–79 (1991).
   PubMed Web of Science ®Google Scholar
• Lugaresi E, Provini F. Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med. Rev.4, 313–322 (2001).
   Google Scholar
• Fantini ML, Corona A, Clerici S, Ferini-Strambi L. Aggressive dream content without daytime aggressiveness in REM sleep behaviour disorder. Neurology65, 1010–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology46, 388–393 (1996).
   PubMed Web of Science ®Google Scholar
• Fantini ML, Gagnon JF, Petit D et al. Slowing of electroencephalogram in rapid eye movement sleep behavior disorder. Ann. Neurol.53, 774–780 (2003).
   PubMed Web of Science ®Google Scholar
• Massicotte-Marquez J, Carrier J, Décary A et al. Slow-wave sleep and delta power in rapid eye movement sleep behavior disorder. Ann. Neurol.57, 277–282 (2005).
   PubMed Web of Science ®Google Scholar
• Celesia GG. The mystery of photopsias, visual hallucinations, and distortions. Suppl. Clin. Neurophysiol.59, 97–103 (2006).
   PubMedGoogle Scholar
• Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J. Neurol. Neurosurg. Psychiatry66, 536–540 (1999).
   PubMed Web of Science ®Google Scholar
• Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson’s disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology45, 1305–1308 (1995).
   PubMed Web of Science ®Google Scholar
• Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology47, 1608–1609 (1996).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson’s disease: preliminary experience. Clin. Neuropharmacol.1, 4–5 (2004).
   Google Scholar
• Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology47, 1085–1087 (1996).
   PubMed Web of Science ®Google Scholar
• Jiménez-Jiménez FJ, Tallón-Barranco A, Ortí-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen Parkinsonism. Neurology50, 1183–1184 (1998).
   PubMedGoogle Scholar
• Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson’s disease. Neurology50, 1195–1196 (1998).
   PubMed Web of Science ®Google Scholar
• Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson’s disease. Mov. Disord.17, 221–225 (2001).
   Google Scholar
• Molho ES, Factor SA. Parkinson’s disease: the treatment of drug-induced hallucinations and psychosis. Curr. Neurol. Neurosci. Rep.14, 320–328 (2001).
   Google Scholar
• Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson’s disease. J. Neuropsychiatr. Clin. Neurosci.12, 364–369 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis among parkinsonian patients. Mov. Disord.19, 831–833 (2004).
   PubMed Web of Science ®Google Scholar
• Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. In: Advances in Neurology, Parkinson’s Disease: From Basic Research to Treatment. Narabayashi N, Nagatsu T, Yanagisawa N, Mizuno Y (Eds). Raven, NY, USA 702–706 (1993).
   Google Scholar
• Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson’s disease with and without dementia. J. Neuropsychiatr. Clin. Neurosci.11, 392–394 (1999).
   PubMedGoogle Scholar
• Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology55, 789–794 (2000).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson sensitive populations. J. Geriatr. Psychiatr. Neurol.15, 156–170 (2002).
   PubMedGoogle Scholar
• Reddy S, Factor S, Molho E, Feustel P. The effect of quetiapine on psychosis and motor function in patients with and without dementia. Mov. Disord.17, 676–681 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov. Disord.18, 510–514 (2003).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Ringholz G. Quetiapine for drug-induced psychosis in Parkinson’s disease: a double-blind, placebo-controlled, parallel trial. Mov. Disord.18, 1083 (2003).
   Google Scholar
• Wolters EC, Hurwitz TA, Mak E et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology40, 832–834 (1990).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N. Engl. J. Med.340, 757–763 (1999).
   PubMed Web of Science ®Google Scholar
• French Clozapine Parkinson Study Group. Clozapine in drug induced psychosis in Parkinson’s disease. Lancet353, 2041–2042 (1999).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.151, 201–211 (2000).
   Google Scholar
• Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov. Disord.12, 483–496 (1997).
   PubMed Web of Science ®Google Scholar
• Friedman JH, Berman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson’s disease. Mov. Disord.21, 2078–2081 (2006).
   PubMed Web of Science ®Google Scholar
• Singh Ajit S. Does aripiprazole have a role in treating cognitive impairment in Parkinson’s disease? J. Neuropsychiatr. Clin. Neurosci.19, 205–206 (2007).
   PubMedGoogle Scholar
• Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson’s disease. Mov. Disord.21, 1538–1539 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez-Meza E, Ruiz-Chow A, Ramirez–Bermudez J. Aripiprazole in psychosis associated with Parkinson’s disease. J. Neuropsychiatr. Clin. Neurosci.17, 421–422 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin. Neuropharmacol.27, 4–5 (2004).
   PubMed Web of Science ®Google Scholar
• Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson’s disease. Funct. Neurol.11, 201–207 (1996).
   PubMed Web of Science ®Google Scholar
• Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson’s disease. J. Geriatr. Psychiatry Neurol.17, 127–136 (2004).
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson’s disease. Clin. Neuropharmacol.23, 287–289 (2000).
   PubMedGoogle Scholar
• Dujardin K, Krystkowiak P, Defebvre L, Blond S, Destée A. A case of severe dysexecutive syndrome consecutive to chronic bilateral pallidal stimulation. Neuropsychologia38, 1305–1315 (2000).
   PubMed Web of Science ®Google Scholar
• Bejjani BP, Damier P, Arnulf I et al. Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med.13, 1476–1480 (1999).
   Google Scholar
• Krack P, Kumar R, Ardouin C et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov. Disord.16, 867–875 (2001).
   PubMed Web of Science ®Google Scholar
• Kuczenski R, Segal DS. Psychomotor stimulant-induced sensitization: behavior and neurochemical correlates. In: Sensitization in the Nervous System. Kalivas PW, Barnes CD (Eds). Telford Press, NJ, USA 177–205 (1988).
   Google Scholar
• Romito LM, Raja M, Daniele A et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson’s disease. Mov. Disord.17, 1371–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain125, 391–403 (2002).
   PubMed Web of Science ®Google Scholar
• Ffytche DH. Visual hallucinations and the Charles Bonnet syndrome. Curr. Psychiatr. Rep.7, 168–179 (2005).
   PubMedGoogle Scholar
• Perry EK, Marshall E, Thompson P et al. Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J. Neural Transm.6, 167–177 (1993).
   Web of Science ®Google Scholar
• Perry EK, Perry RH. Acetylcholine and hallucinations: disease related compared to drug-induced alterations in human consciousness. Brain Cogn.28, 240–258 (1995).
   PubMed Web of Science ®Google Scholar
• Teaktong T, Piggott MA, Mckeith IG, Perry RH, Ballard CG, Perry EK. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav. Brain Res.161, 299–305 (2005).
   PubMed Web of Science ®Google Scholar
• Perry EK, Marshall E, Kerwin J et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J. Neurochem.55, 1454–1456 (1990).
   PubMed Web of Science ®Google Scholar
• Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci.22, 273–280 (1999).
   PubMed Web of Science ®Google Scholar
• Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study. Mov. Disord.21, 456–461 (2006).
   PubMed Web of Science ®Google Scholar
• Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord.16, 1171–1195 (2001).
   PubMed Web of Science ®Google Scholar
• McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement. Geriatr. Cogn Disord.18, 94–100 (2004).
   PubMed Web of Science ®Google Scholar
• Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann. Neurol.54, 235–238 (2003).
   Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol.5, 235–245 (2006).
   PubMed Web of Science ®Google Scholar
• Bodis-Wollner I, Onofrj M. Visual system in Parkinson’s disease. In: Advances in Neurology. Yahr MD, Bergmann KJ (Eds). 45, 323–327 (1986).
   Google Scholar
• Ghilardi MF, Bodis-Wollner I, Onofrj M, Marx MS, Glover AA. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain3, 131–149 (1988).
   Google Scholar
• Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson’s disease. Brain101, 667–671 (1979).
   Google Scholar
• Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov. Disord.5, 280–285 (1990).
   PubMed Web of Science ®Google Scholar
• Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson’s disease patients with treatment induced hallucinations. Ann. Neurol.34, 710–714 (1993).
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov. Disord.20, 1439–1448 (2005).
   PubMed Web of Science ®Google Scholar
• Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav. Brain Sci.23, 793–842; discussion 904–1121 (2000).
   PubMed Web of Science ®Google Scholar
• Takata K, Inoue Y, Hazama H, Fukuma E. Night-time hypnopompic visual hallucinations related to REM sleep disorder. Psychiatry Clin. Neurosci.52, 207–209 (1998).
   PubMedGoogle Scholar
• Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep–wake cycle in PD. Neurology59, 1979–1981 (2002).
   PubMed Web of Science ®Google Scholar
• Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov. Disord.18, 812–817 (2003).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Luciano AL, Iacono D et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson’s disease. Mov. Disord.18, 337–340 (2003).
   PubMedGoogle Scholar
• Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioural disorders of human REM sleep: a new category of parasomnia. Sleep9, 293–308 (1986).
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Onofrj M. Symptomatic REM sleep behaviour disorder. Neurol Sci.28(Suppl. 1), S21–S36 (2007).
   PubMedGoogle Scholar
• Onofrj M, Curatola L, Ferracci F, Fulgente T. Narcolepsy associated with primary temporal lobe β-cells lymphoma in a HLA DR2 negative subject. J. Neurol. Neurosurg. Psychiatry55, 852–853 (1992).
   PubMedGoogle Scholar
• Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson’s disease. Brain130, 1586–1595 (2007).
   PubMed Web of Science ®Google Scholar
• Oka H, Yoshioka M, Onouchi K et al. Impaired cardiovascular autonomic function in Parkinson’s disease with visual hallucinations. Mov. Disord.22, 1510–1514 (2007)
   PubMedGoogle Scholar
• Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson’s disease. J. Neurol. Sci. (2007) (Epub ahead of print).
   Google Scholar
• Owen AM. Cognitive dysfunction in Parkinson’s disease: the role of frontostriatal circuitry. Neuroscientist6, 525–537 (2004).
   Google Scholar
• Goldberg E. The Executive Brain. Oxford University Press, NY, USA 1–251 (2001).
   Google Scholar
• Goldberg E. Gradiental approach to neocortical functional organization. J. Clin. Exp. Neuropsychol.4, 489–517 (1989).
   Google Scholar
• Goldberg E. The frontal lobes in neurological and psychiatric conditions. Neuropsychiatry Neuropsychol. Behav. Neurol.5, 231–232 (1992).
   Google Scholar
• Treisman A. Features and objects: the fourteenth Bartlett memorial lecture. Q. J. Exp. Psychol. A40, 201–237 (1988).
   PubMedGoogle Scholar
• Stebbins GT, Goetz CG, Carrillo MC et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology63, 1409–1416 (2004).
   PubMed Web of Science ®Google Scholar
• Ramírez-Ruiz B, Martí MJ, Tolosa E et al. Longitudinal evaluation of cerebral morphological changes in Parkinson’s disease with and without dementia. J. Neurol.11, 1345–1352 (2005)
   Google Scholar
• Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov. Disord. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Borek LL, Kohn R, Friedman JH. Phenomenology of dreams in Parkinson’s disease. Mov. Disord.22(2), 198–202 (2007).
   PubMed Web of Science ®Google Scholar
• Mathis J, Hess CW, Bassetti C. Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder. J. Neurol. Neurosurg. Psychiatry78, 427–429 (2007)
   PubMedGoogle Scholar
• Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology67, 742–747 (2006).
   PubMedGoogle Scholar
• Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology61, 1452 (2003).
   PubMedGoogle Scholar
• Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series. Curr. Med. Res. Opin.18, 258–264 (2002).
   PubMed Web of Science ®Google Scholar
• Kolmel HW. Peduncular hallucinations. J. Neurol.8, 457–459 (1991).
   Google Scholar
• Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J. Neuropsychiatr. Clin. Neurosci.13, 42–49 (2001).
   PubMed Web of Science ®Google Scholar
• Papapetropoulos S, Mash DC. Visual hallucinations in progressive supranuclear palsy. Eur. Neurol.54, 217–219 (2005).
   PubMedGoogle Scholar
• Nagano-Saito A, Washimi Y, Arahata Y et al. Visual hallucination in Parkinson’s disease with FDG PET. Mov. Disord.7, 801–806 (2004).
   Google Scholar
• Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology65, 1708–1715 (2005).
   PubMed Web of Science ®Google Scholar
• Holroyd S, Wooten GF. Preliminary fMRI evidence of visual system dysfunction in Parkinson’s disease patients with visual hallucinations. J. Neuropsychiatr. Clin. Neurosci.3, 402–404 (2006).
   Google Scholar
• Molho ES, Factor SA. Parkinson’s disease: the treatment of drug induced hallucinations and psychosis. Curr. Neurol. Neurosci. Rep.1, 320–328 (2001).
   PubMedGoogle Scholar
• Juncos JL. Management of psychotic aspects of Parkinson’s disease. J. Clin. Psychiatry60(Suppl. 8), 42–53 (1999).
   PubMedGoogle Scholar
• Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson’s disease. Mov. Disord.2, 201–211 (2000).
   Google Scholar
• Movement Disorders Society. Management of Parkinson’s disease: an evidence-based review drugs to treat dementia and psychosis. Mov. Disord.17(Suppl. 4), S120–S127 (2002).
   Google Scholar
• Poewe W. Psychosis in Parkinson’s disease. Mov. Disord.18(Suppl. 6), S80–S87 (2003).
   PubMedGoogle Scholar
• Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur. Neuropsychopharmacol.3, 165–171 (2007).
   Google Scholar
• Seppi K, Sampaio C, Sawires M, Costa J, Poewe W. Treatment of psychosis in Parkinson’s disease. (Protocol) The Cochrane Collaboration. Cochrane Database of Systematic Reviews 4 (2007).
   Google Scholar
• Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson’s disease patients with psychosis. Neurology44, 544–546 (1994).
   PubMed Web of Science ®Google Scholar
• Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol.27, 153–156 (2004).
   PubMed Web of Science ®Google Scholar
• Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosis. Clin. Neuropharmacol.29, 331–337 (2006).
   PubMed Web of Science ®Google Scholar
• Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord.17, 1031–1035 (2002).
   PubMed Web of Science ®Google Scholar
• Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic -induced psychosis in patients with Parkinson’s disease. Biol. Psychiatry52, 438–445 (2002).
   PubMed Web of Science ®Google Scholar
• Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov. Disord.15, 301–304 (2000).
   PubMed Web of Science ®Google Scholar
• Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson’s disease: an open pilot trial. Mov. Disord.6, 1230–1237 (2000).
   Google Scholar
• Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov. Disord.22, 313–318 (2007).
   PubMed Web of Science ®Google Scholar
• Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic parkinsonian patients with and without dementia an open-labeled study utilizing a structured interview. J. Neurol.253, 171–175 (2006).
   PubMed Web of Science ®Google Scholar
• Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin. Neuropharmacol.29, 215–219 (2006).
   PubMed Web of Science ®Google Scholar
• Juncos JL, Roberts VJ, Evatt ML et al. Quetiapine improves psychotic symptoms and cognition in Parkinson’s disease. Mov. Disord.1, 29–35 (2004).
   Google Scholar
• Rudolf J, Grond M, Neveling M, Heiss W. Clozapine-induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J. Neural. Transm.104, 1305–1311 (1997).
   PubMed Web of Science ®Google Scholar
• Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov. Disord.8, 1061–1068 (2007).
   Google Scholar
• Fernandez HH, Trieschmann ME, Okun MS. “Rebound psychosis”: effect of discontinuation of antipsychotics in Parkinson’s disease. Mov. Disord.20, 104–105 (2005).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology64, 1162–1169 (2005).
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, Armellino K, Onofrj M. Acute akinesia or akinetic crisis in Parkinson’s disease. Neurol. Sci.3, 219–220 (2003).
   Google Scholar
• Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL. Psychiatric complications of levodopa therapy of Parkinson’s disease. Adv. Neurol.40, 271–277 (1984).
   PubMedGoogle Scholar
• Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs5, 773–794 (1996).
   Google Scholar
• Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson’s disease. Prog. Neuropsychopharmacol. Biol. Psychiatry31, 311–313 (2007).
   PubMed Web of Science ®Google Scholar
• Schindehütte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson’s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin. Neurol. Neurosurg.109, 188–191 (2007).
   PubMed Web of Science ®Google Scholar
• Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson’s disease. Mov. Disord.18, 812–817 (2003).
   PubMed Web of Science ®Google Scholar
• Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson’s disease. J. Geriatr. Psychiatry Neurol.16, 184–188 (2003)
   Google Scholar
• Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry72, 708–712 (2002).
   PubMed Web of Science ®Google Scholar
• Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease. Neurol. Sci.23, 41–43 (2002).
   PubMed Web of Science ®Google Scholar
• Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementia. Int. J. Geriatr. Psychiatry18, 937–941 (2003).
   PubMed Web of Science ®Google Scholar
• Sobow T. Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol. Neurochir. Pol.41, 276–279 (2007).
   PubMed Web of Science ®Google Scholar
• Gugger JJ, Wagner ML. Rapid eye movement sleep behavior disorder. Ann. Pharmacother.41, 1833–1841 (2007)
   Google Scholar
• Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson’s disease. Parkinsonism Relat. Disord.9, S83–S89 (2003)
   Web of Science ®Google Scholar
• Arnulf I., Bonnet Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson’s disease. Invest. Ophthalmol. Vis. Sci.31, 2473–2475 (1990)
   PubMedGoogle Scholar
• Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci.13, 296–302 (1990).
   PubMed Web of Science ®Google Scholar
• Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin. Neuropharmacol.21, 289–295 (1998).
   PubMed Web of Science ®Google Scholar
• Pieri V, Diedrich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson’s disease. J. Neurol. Sci.172, 7–11 (2000).
   PubMed Web of Science ®Google Scholar
• Maurage CA, Ruchoux MM, de Vos R, Surguchov A, Destee A. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations. Ann. Neurol.54, 542–247 (2003).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bodis-Wollner I. Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann. Neurol.11, 484–490 (1982).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Ghilardi MF, Basciani M, Gambi D. Visual evoked potentials in Parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J. Neurol. Neurosurg. Psychiatry49, 1150–1159 (1986).
   PubMed Web of Science ®Google Scholar
• Ghilardi MF, Chung E, Bodis–Wollner I, Dvorzniak M, Glover A, Onofrj M. Systemic 1-methyl, 4-phenyl, 1–2-3–6 tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci.43, 255–262 (1988).
   PubMedGoogle Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology44, 2308–2314 (1994).
   PubMed Web of Science ®Google Scholar
• Ichikawa J, Li Z, Dai J, Meltzer HY. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res.956, 349–357 (2002).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M et al. Safinamide Parkinson’s Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology63, 746–748 (2004).
   PubMed Web of Science ®Google Scholar
• Onofrj M, Luciano AL, Thomas A, Iacono D, D’Andreamatteo G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology60, 113–115 (2003).
   PubMedGoogle Scholar